Medical Health & Life Science Research News

New report shares details about the smoking addiction pipeline overview for H1 2017

The Smoking Addiction Pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- Agency -.

H1 2017 Smoking Addiction Pipeline report covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Smoking Addiction Pipeline 2017 - Drug Profiles : AKR-214, amitifadine, Anatabine, AT-1001, BP-1.4979, cytosine, GTS-21, JLP-1603, JNJ-39393406, nadolol, NFL-101, NIC-7DT, nicotine, nicotine bitartrate, nicotine bitartrate, PF-06413367, SEL-068, SEL-070, Small Molecule to Antagonize Cannabinoid Receptor, Suppression and Smoking Cessation, URB-694, Vaccine for Smoking Addiction.

Get Smoking Addiction Pipeline Review Report 2017@ www.reportsnreports.com/contacts/discount.aspx?name=1057932 .

Smoking Addiction - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Smoking Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

- Agency -.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Access Complete Report On Smoking Addiction Pipeline Review H1 2017: www.reportsnreports.com/purchase.aspx?name=1057932

Companies : Aradigm Corp, Bionex Pharmaceuticals LLC, Bioprojet SCR, CoMentis Inc, Embera NeuroTherapeutics Inc, Invion Ltd, Jeil Pharmaceutical Co Ltd, Johnson & Johnson, Lotus Pharmaceutical Co Ltd, NAL Pharmaceuticals Ltd, Pfizer Inc, Rock Creek Pharmaceuticals, Inc., Selecta Biosciences Inc, Sopharma AD, Zynerba Pharmaceuticals Inc

In smoking addiction, people experience an uncontrollable dependence on cigarettes, which on stopping will cause severe mental, emotional or physical reactions. People addicted to smoking develop tolerance to nicotine.

Nicotine acts on acetylcholine receptors causing the body to react to nicotine at these receptors in the same manner as it responds to acetylcholine. This leads to alterations in the activity and physiological functions of many brain systems.

This causes structural and functional changes in the brains of smokers. Upon sudden nicotine withdrawal, the brain and other parts of the body get disturbed, leading to a condition called withdrawal syndrome.

The body usually takes time to function in the absence of nicotine. The effects of smoking withdrawal stem from the lack of nicotine that can be overcome by nicotine replacement therapies such as the use of nicotine patch or nicotine chewing gum.

The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

The report provides a snapshot of the global therapeutic landscape of Smoking Addiction. The report reviews pipeline therapeutics for Smoking Addiction by companies and universities/research institutes based on information derived from company and industry-specific sources.

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.

The report reviews key players involved Smoking Addiction therapeutics and enlists all their major and minor projects. The report assesses Smoking Addiction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The report summarizes all the dormant and discontinued pipeline projects. The report reviews latest news related to pipeline therapeutics for Smoking Addiction

List of Figures
Number of Products under Development for Smoking Addiction, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

News From

ReportsnReports - Industry Trends & ForecastsReportsnReports
Category: Market Research Publishers and RetailersCompany profile: ReportsnReports.com provides market research reports to industries, individuals and organizations with an objective of helping them in their decision-making process. Our library of 400,000+ industry & country research reports covers 5000+ micro markets.